BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 33692216)

  • 1. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.
    Seo I; Lee HW; Byun SJ; Park JY; Min H; Lee SH; Lee JS; Kim S; Bae SU
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
    Machackova T; Trachtova K; Prochazka V; Grolich T; Farkasova M; Fiala L; Sefr R; Kiss I; Skrovina M; Dosoudil M; Berindan-Neagoe I; Svoboda M; Slaby O; Kala Z
    Cancer Genomics Proteomics; 2020; 17(3):249-257. PubMed ID: 32345666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.
    Yu J; Li N; Wang X; Ren H; Wang W; Wang S; Song Y; Liu Y; Li Y; Zhou X; Luo A; Liu Z; Jin J
    Oncotarget; 2016 Sep; 7(39):64233-64243. PubMed ID: 27572313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer.
    Wilkins A; Fontana E; Nyamundanda G; Ragulan C; Patil Y; Mansfield D; Kingston J; Errington-Mais F; Bottomley D; von Loga K; Bye H; Carter P; Tinkler-Hundal E; Noshirwani A; Downs J; Dillon M; Demaria S; Sebag-Montefiore D; Harrington K; West N; Melcher A; Sadanandam A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33678606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Expression of VSTM2L Induced Resistance to Chemoradiotherapy in Rectal Cancer through Downstream IL-4 Signaling.
    Liu H; Zhang Z; Zhen P; Zhou M
    J Immunol Res; 2021; 2021():6657012. PubMed ID: 33506057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSMB8 as a Candidate Marker of Responsiveness to Preoperative Radiation Therapy in Rectal Cancer Patients.
    Ha YJ; Tak KH; Kim CW; Roh SA; Choi EK; Cho DH; Kim JH; Kim SK; Kim SY; Kim YS; Kim JC
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1164-1173. PubMed ID: 28721901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
    Helbling D; Bodoky G; Gautschi O; Sun H; Bosman F; Gloor B; Burkhard R; Winterhalder R; Madlung A; Rauch D; Saletti P; Widmer L; Borner M; Baertschi D; Yan P; Benhattar J; Leibundgut EO; Bougel S; Koeberle D
    Ann Oncol; 2013 Mar; 24(3):718-25. PubMed ID: 23139259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ku70, Ku80, and sClusterin: A Cluster of Predicting Factors for Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer.
    Pucci S; Polidoro C; Joubert A; Mastrangeli F; Tolu B; Benassi M; Fiaschetti V; Greco L; Miceli R; Floris R; Novelli G; Orlandi A; Santoni R
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):381-388. PubMed ID: 28068245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma.
    D'Angelo E; Zanon C; Sensi F; Digito M; Rugge M; Fassan M; Scarpa M; Pucciarelli S; Nitti D; Agostini M
    J Clin Pathol; 2018 Apr; 71(4):344-350. PubMed ID: 28870889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.
    Alderdice M; Dunne PD; Cole AJ; O'Reilly PG; McArt DG; Bingham V; Fuchs MA; McQuaid S; Loughrey MB; Murray GI; Samuel LM; Lawler M; Wilson RH; Salto-Tellez M; Coyle VM
    Mod Pathol; 2017 Sep; 30(9):1287-1298. PubMed ID: 28621318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer.
    Agostini M; Janssen KP; Kim IJ; D'Angelo E; Pizzini S; Zangrando A; Zanon C; Pastrello C; Maretto I; Digito M; Bedin C; Jurisica I; Rizzolio F; Giordano A; Bortoluzzi S; Nitti D; Pucciarelli S
    Oncotarget; 2015 Oct; 6(32):32561-74. PubMed ID: 26359356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsatellite instability and response to neoadjuvant chemoradiotherapy in rectal cancer: A systematic review and meta-analysis.
    O'Connell E; Reynolds IS; McNamara DA; Prehn JHM; Burke JP
    Surg Oncol; 2020 Sep; 34():57-62. PubMed ID: 32891354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profiling of rectal tumors defines response to neoadjuvant treatment related genes.
    Palma P; Cano C; Conde-Muiño R; Comino A; Bueno P; Ferrón JA; Cuadros M
    PLoS One; 2014; 9(11):e112189. PubMed ID: 25380052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic landscape of locally advanced rectal adenocarcinoma: Comparison between before and after neoadjuvant chemoradiation and effects of genetic biomarkers on clinical outcomes and tumor response.
    Lee TH; Jang BS; Chang JH; Kim E; Park JH; Chie EK
    Cancer Med; 2023 Jul; 12(14):15664-15675. PubMed ID: 37260182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
    Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
    PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of pathological response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer.
    Tomono A; Yamashita K; Kanemitsu K; Sumi Y; Yamamoto M; Kanaji S; Imanishi T; Nakamura T; Suzuki S; Tanaka K; Kakeji Y
    Int J Clin Oncol; 2016 Apr; 21(2):344-349. PubMed ID: 26338272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation.
    Schollbach J; Kircher S; Wiegering A; Anger F; Rosenwald A; Germer CT; Löb S
    Int J Colorectal Dis; 2020 Feb; 35(2):365-370. PubMed ID: 31828368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review.
    Mori R; Uemura M; Sekido Y; Hata T; Ogino T; Takahashi H; Miyoshi N; Mizushima T; Doki Y; Eguchi H
    World J Surg Oncol; 2022 May; 20(1):166. PubMed ID: 35619103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
    Russo AL; Ryan DP; Borger DR; Wo JY; Szymonifka J; Liang WY; Kwak EL; Blaszkowsky LS; Clark JW; Allen JN; Zhu AX; Berger DL; Cusack JC; Mamon HJ; Haigis KM; Hong TS
    J Gastrointest Cancer; 2014 Mar; 45(1):34-9. PubMed ID: 24006244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.